Combivent Respimat Asthma Inhalers
In May 2019, a class-action lawsuit was filed against Boehringer Ingelheim Pharmaceuticals for allegedly deceptively marketing that the Combivent Respimat asthma inhaler will provide 120 doses when, according to plaintiffs, the inhaler contains far fewer dosages, sometimes less than half the advertised amount. (Ignacuinos et al v. Boehringer Ingelheim Pharmaceuticals, Inc., Case No. 19-cv-672, D. Conn.)
The Latest
Audiobooks on Spotify
Don’t judge this Spotify feature by its cover.
Kouvr Fashion
Don’t be fooled by this website.
Verizon Super Bowl FanFest
Verizon Super Bowl FanFest is hitting 30 cities for a Super Bowl experience like no other. You In?
Magic Styler’s Refund Policy
This risk-free trial might have you pulling your hair out.